Source comparison
BPC-157 Comparison: Oral vs Injectable vs Alternative Peptides
Bioavailability Unknown. Stable in gastric acid but first-pass metabolism unclear High local concentration at injection site; systemic clearance within 4–6 hours Systemic distribution; longer half-life than BPC-157 Subcutaneous BPC-157 near injury site offers
This comparison does not assign a generated winner or score.
- Bioavailability
- Unknown. Stable in gastric acid but first-pass metabolism unclear
- High local concentration at injection site; systemic clearance within 4–6 hours
- Systemic distribution; longer half-life than BPC-157
- Subcutaneous BPC-157 near injury site offers best site-specific effect
- Mechanism
- Systemic effect only; no localized concentration
- Localized upregulation of VEGF and FAK-paxillin at injury site
- Upregulates actin in all tissues; promotes cell migration globally
- BPC-157 targets injury-specific pathways; TB-500 is broader
- Typical Dose
- 500–1000 mcg/day (2–3x injectable dose to compensate for gut loss)
- 250–500 mcg/day split into 2 injections
- 2–5 mg/week (much higher mg dose, less frequent)
- Injectable BPC-157 requires less total peptide per week
- Onset of Subjective Effect
- 7–14 days in anecdotal reports
- 3–7 days in anecdotal reports
- 5–10 days in anecdotal reports
- Subcutaneous shows fastest subjective improvement
- Regulatory Status
- Not FDA-approved; sold as research chemical
- All three exist in the same grey zone
- Cost per 30-Day Cycle
- $40–$80 depending on vendor
- $60–$120 depending on vendor and dose
- $150–$300 depending on vendor and dose
- Oral is cheapest but least targeted
- This table shows that powerlifters researching BPC-157 choose between site-specific repair (subcutaneous) and convenience (oral). Most prioritize the former because the localized effect is the primary reason for using BPC-157 over systemic anti-inflammatories. TB-500 is an alternative peptide that also promotes tissue repair but works through a different mechanism (actin upregulation rather than VEGF and FAK-paxillin modulation) and costs significantly more per cycle.